← All trials
NCT07239414
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 10, 2025
- Primary completion
- Nov 10, 2026
- Completion date
- Feb 21, 2027
- First posted
- Nov 20, 2025
- Last posted
- Nov 20, 2025
- Enrollment
- 690
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sheikh Zayed Medical CollegeLead sponsor
- Sheikh Zayed Medical CollegeSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.